- RecruitingPHASE3
Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)
This study is looking into a new medication called VGA039 for people with Von Willebrand Disease (VWD). It's a Phase 3 trial, meaning it's a later stage of research, testing if this medicine can safely and effectively reduce bleeding when given as an injection under the skin.
For: Von Willebrand Disease (VWD)United States · Georgia · Germany - RecruitingPHASE1, PHASE2
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
This study, called VIVID, is looking at a new medicine for Von Willebrand Disease (VWD) and other bleeding problems. It involves healthy volunteers and people with WVD, testing different ways of giving the medicine, either through a vein or under the skin.
For: Von Willebrand DiseasesUnited States · Australia · Austria